Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
about
Update on the Management of Aspirin-Exacerbated Respiratory DiseaseAspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the futureEosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.Chronic Rhinosinusitis: More Than Just "Asthma of the Upper Airway"Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.Aspirin-exacerbated respiratory disease: not always "adult-onset"Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors.Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory diseaseCurrent and future biomarkers in allergic asthma.Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation PathwaySphingosine-1-phosphate and other lipid mediators generated by mast cells as critical players in allergy and mast cell functionUtility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.Cyclooxygenase 2: its regulation, role and impact in airway inflammation.Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease.Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.Update on Aspirin-Exacerbated Respiratory Disease.Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.Prostaglandins and Their Receptors in Eosinophil Function and As Therapeutic Targets.Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.Potential Biomarkers for NSAID-Exacerbated Respiratory DiseasePhysiopathology and genetics in aspirin-exacerbated respiratory disease.Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.An update on the management of aspirin-exacerbated respiratory disease.Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial.Comment on: "Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives".Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma.Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease.
P2860
Q26749097-A07B9070-FF2F-4B1A-A972-E306BD0DCC2FQ30238776-47FA0E07-F406-44A5-AF00-EB3AAFB0DAE4Q30275780-712CCB5D-E13F-4611-A15B-EDD8B1FD58E0Q30276354-D599E305-18C5-4A0A-AF4C-A737DE5E56C9Q30278686-E1483906-0E3A-4656-993A-8A3B2110CE8CQ30279219-41CC5202-BCDD-410F-B629-01079CE33B24Q30407185-C3259491-0F63-4DB4-A61D-8C935AA0E2B3Q33772263-EE4114CF-5BFE-4FD2-930A-B5AE2FD3E2DDQ34473270-C8D1598D-12B3-43B6-982F-D0AE8A8E9E9BQ35589545-79CACF11-C098-418C-8052-08E742F4B679Q35878914-BF5878CD-4C45-4DE3-8317-F6BAFD81D354Q36119388-3AA89926-1505-40CC-A76D-26FBB460847EQ36240870-38C70E70-5F38-45FC-A6AA-299FE7CC9A73Q36782772-59A70E89-C306-4E7E-857A-25E375D67C63Q38674101-B8B726E8-3215-4577-9961-FA250FAEE271Q38891410-DC3E5A78-93B6-417D-BBB9-4F2E77D56366Q38916857-47BA55CF-BAEA-4F02-89A3-CC8DFD27C804Q38973949-F52721FE-E07F-4107-9C1A-5B1E0FD03091Q39093155-D1DABFF5-B7E8-4CC2-9A47-AAE334DC24BBQ39175214-9116FDD9-B916-4591-8881-9BB97C988DCAQ41050351-46D12CF5-3E56-4324-A545-D3D54557C37DQ41146048-FE73F647-4E79-4F58-B430-FDFEC2483322Q41500425-A2B6E141-ED0C-4A83-9ED1-44F06C578599Q47649225-3E97D5A9-87A7-4C06-A264-2E040589C6AFQ47656375-2F310257-A919-4CE7-AA81-5F146533A21FQ47678797-4D379AFE-BFEB-4673-9841-0AE305E2190EQ47713321-0752ED34-369D-4259-99AB-AC812FC74D80Q47916155-7CF4A1F4-8EB4-48D3-B69A-1722EBF6DDB7Q47982119-3173B534-9F57-44CC-A1B1-5C281C8DAB9DQ50796212-EDA50A32-9E03-4196-B73B-0B81ED34FF70Q51469727-A5EE22C9-39BB-4435-88FF-FFB41EA9601E
P2860
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@ast
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@en
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@nl
type
label
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@ast
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@en
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@nl
prefLabel
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@ast
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@en
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@nl
P2093
P2860
P1476
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
@en
P2093
Jillian C Bensko
Joshua A Boyce
Katherine N Cahill
Tanya M Laidlaw
P2860
P304
P356
10.1016/J.JACI.2014.07.031
P407
P577
2014-09-11T00:00:00Z